School personnel information

写真b

KUBOTA Takuo


Keyword

Bone and Mineral Metabolism, Pediatric Endocrinolody

URL

http://www.med.osaka-u.ac.jp/pub/ped/www/Welcome-jp.html

Organization 【 display / non-display

  • 2011.11.01 - 2015.03.31, Osaka University Dental Hospital, Assistant Professor

  • 2015.04.01 - 2018.03.31, Graduate School of Medicine, Assistant Professor

  • 2018.04.01 - , Graduate School of Medicine, Associate Professor

Research topics 【 display / non-display

  • Pediatrics
    Embryonic medicine and pediatrics-related

Academic Society Membership 【 display / non-display

  • The American Society for Bone and Mineral Research

 

Academic Papers 【 display / non-display

  • Parental somatogonadal COL2A1 mosaicism contributes to intrafamilial recurrence in a family with type 2 collagenopathy, Yamamoto K, Kubota T, Takeyari S, Kitaoka T, Miyata K, Nakano Y, Nakayama H, Ohata Y, Yanagi K, Kaname T, Okada Y, Ozono K, The American Journal of Medical Genetics - Part A , 2020.03, Papers

  • Comprehensive genetic analyses using targeted next-generation sequencing and genotype-phenotype correlations in 53 Japanese patients with osteogenesis imperfecta, Yasuhisa Ohata,30 2333-2342, 2019.11, Papers

  • Genotype-phenotype characteristics in four families of type II collagenopathy in our hospital, Yamamoto Kenichi, Kubota Takuo, Takeyari Shinji, Nakano Yukako, Nakayama Hirofumi, Fujiwara Makoto, Ohata Yasuhisa, Kitaoka Taichi, Miyoshi Yoko, Ozono Keiichi, HORMONE RESEARCH IN PAEDIATRICS,91 210, 2019.09, Other

  • Comprehensive genetic analyses using targeted next-generation sequencing and genotype-phenotype correlations in 53 Japanese patients with osteogenesis imperfecta, Ohata Y, Takeyari S, Nakano Y, Kitaoka T, Nakayama H, Bizaoui V, Yamamoto K, Miyata K, Yamamoto K, Fujiwara M, Kubota T, Michigami T, Yamamoto K, Yamamoto T, Namba N, Ebina K, Yoshikawa H, Ozono K, Osteoporos Int., 2019.08, Papers

  • Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period., Portale AA, Carpenter TO, Brandi ML, Briot K, Cheong HI, Cohen-Solal M, Crowley R, Jan De Beur S, Eastell R, Imanishi Y, Imel EA, Ing S, Ito N, Javaid M, Kamenicky P, Keen R, Kubota T, Lachmann R, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Zhang L, Theodore-Oklota C, Mealiffe M, San Martin J, Insogna K, Calcified tissue international,105(3) 271-284, 2019.06, Other

display all >>